NIVANEX DMX- guaifenesin, dextromethorphan hydrobromide, and phenylephrine hydrochloride tablet 
Nivagen Pharmaceuticals, Inc.

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

----------

Nivanex DMX™

Drug Facts

Active ingredients (in each Tablet)Purpose
Dextromethorphan HBr 15 mgCough Suppressant
Guaifenesin 380 mgExpectorant
Phenylephrine HCl 10 mgNasal Decongestant

Uses

Temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies:

Warnings

Do not exceed recommended dosage.

Do not use this product

  • if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. If you do not know if your prescription drug contains an MAOI, ask a doctor or pharmacist before taking this product.

Ask a doctor before use if you have

  • a cough that lasts or is chronic such as occurs with smoking, asthma, chronic bronchitis, or emphysema
  • a cough that occurs with too much phlegm (mucus)
  • heart disease
  • high blood pressure
  • thyroid disease
  • diabetes
  • trouble urinating due to an enlarged prostate gland

Stop use and ask a doctor if

  • nervousness, dizziness, or sleeplessness occur
  • cough or nasal congestion persists for more than 1 week, tends to recur, or is accompanied by a fever, rash, or persistent headache. A persistent cough may be a sign of a serious condition.
  • new symptoms occur

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Directions

Do not exceed recommended dosage.

Adults and children 12 years of age and over1 tablet every 4 hours, not to exceed 6 tablets in 24 hours.
Children 6 to under 12 years of age1/2 tablet every 4 hours, not to exceed 3 tablets in 24 hours.
Children under 6 years of ageConsult a physician.

Other information

Store at controlled room temperature 15º - 30ºC (59º-86ºF).

Inactive ingredients

D&C Yellow # 10, FD&C Yellow # 6, Magnesium Stearate, Microcrystalline Cellulose, Sodium Starch Glycolate.

Distributed by: Nivagen Pharmaceuticals, Inc
Sacramento, CA 95827 USA
Customer Service Number: 1-877-977-0687

PRINCIPAL DISPLAY PANEL - 60 Tablet Bottle Label

NDC 75834-040-60

NIVAGEN
PHARMACEUTICALS

Nivanex DMX™

COUGH SUPPRESSANT • EXPECTORANT
NASAL DECONGESTANT

EACH TABLET CONTAINS:
Dextromethorphan HBr
15 mg
Guaifenesin
380 mg
Phenylephrine HCl
10 mg

Tamper evident by foil seal under cap.
Do not use if foil seal is broken or missing

60 TABLETS

PRINCIPAL DISPLAY PANEL - 60 Tablet Bottle Label
NIVANEX DMX 
guaifenesin, dextromethorphan hydrobromide, and phenylephrine hydrochloride tablet
Product Information
Product TypeHUMAN OTC DRUGItem Code (Source)NDC:75834-040
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
GUAIFENESIN (UNII: 495W7451VQ) (GUAIFENESIN - UNII:495W7451VQ) GUAIFENESIN380 mg
DEXTROMETHORPHAN HYDROBROMIDE (UNII: 9D2RTI9KYH) (DEXTROMETHORPHAN - UNII:7355X3ROTS) DEXTROMETHORPHAN HYDROBROMIDE15 mg
PHENYLEPHRINE HYDROCHLORIDE (UNII: 04JA59TNSJ) (PHENYLEPHRINE - UNII:1WS297W6MV) PHENYLEPHRINE HYDROCHLORIDE10 mg
Inactive Ingredients
Ingredient NameStrength
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
MAGNESIUM STEARATE (UNII: 70097M6I30)  
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)  
Product Characteristics
ColorYELLOWScore2 pieces
ShapeOVALSize16mm
FlavorImprint Code N040
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:75834-040-6060 in 1 BOTTLE; Type 0: Not a Combination Product11/24/2014
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
OTC MONOGRAPH FINALpart34111/24/2014
Labeler - Nivagen Pharmaceuticals, Inc. (052032418)

Revised: 2/2022
Document Id: 325d6315-5d2b-49d6-b5b7-b5918c48c048
Set id: 9493e845-1b83-42c5-a7b5-ff3f3232e794
Version: 5
Effective Time: 20220214
 
Nivagen Pharmaceuticals, Inc.